Amyris (NASDAQ:AMRS) Hits New 52-Week Low at $1.45

Amyris, Inc. (NASDAQ:AMRSGet Rating) shares reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $1.45 and last traded at $1.66, with a volume of 825128 shares. The stock had previously closed at $2.59.

Analysts Set New Price Targets

AMRS has been the topic of several research reports. Oppenheimer lowered Amyris from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Cowen reduced their price target on Amyris from $13.00 to $6.00 in a research report on Thursday. Roth Capital lowered Amyris from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 10th. Piper Sandler increased their price target on Amyris from $2.50 to $4.00 and gave the company a “neutral” rating in a research report on Monday, September 19th. Finally, Cowen reduced their price target on Amyris from $13.00 to $6.00 in a research report on Thursday. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.33.

Amyris Stock Performance

The company has a market cap of $595.13 million, a price-to-earnings ratio of -1.06 and a beta of 1.22. The business has a 50-day simple moving average of $2.93 and a 200-day simple moving average of $2.62.

Amyris (NASDAQ:AMRSGet Rating) last issued its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). The firm had revenue of $65.20 million during the quarter, compared to analyst estimates of $81.53 million. During the same quarter in the previous year, the business earned ($0.16) earnings per share. The business’s quarterly revenue was up 24.7% on a year-over-year basis. Research analysts anticipate that Amyris, Inc. will post -1.11 EPS for the current year.

Insider Transactions at Amyris

In other news, Director Frank Kung sold 1,385,000 shares of the firm’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $4.20, for a total transaction of $5,817,000.00. Following the sale, the director now owns 458,591 shares of the company’s stock, valued at approximately $1,926,082.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 2,665,676 shares of company stock valued at $10,623,569. Corporate insiders own 33.80% of the company’s stock.

Institutional Investors Weigh In On Amyris

Hedge funds and other institutional investors have recently made changes to their positions in the business. Envestnet Asset Management Inc. grew its stake in Amyris by 34.1% during the 3rd quarter. Envestnet Asset Management Inc. now owns 158,775 shares of the biotechnology company’s stock worth $464,000 after buying an additional 40,359 shares during the last quarter. Credit Suisse AG grew its stake in Amyris by 43.9% during the 3rd quarter. Credit Suisse AG now owns 3,109,050 shares of the biotechnology company’s stock worth $9,079,000 after buying an additional 949,232 shares during the last quarter. Strategic Wealth Advisors Group LLC purchased a new position in Amyris during the 3rd quarter worth approximately $304,000. Edmond DE Rothschild Holding S.A. grew its stake in Amyris by 4.7% during the 3rd quarter. Edmond DE Rothschild Holding S.A. now owns 7,293,700 shares of the biotechnology company’s stock worth $21,298,000 after buying an additional 328,000 shares during the last quarter. Finally, Atom Investors LP purchased a new position in Amyris during the 3rd quarter worth approximately $37,000. Institutional investors and hedge funds own 43.08% of the company’s stock.

Amyris Company Profile

(Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

See Also

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.